37 results about "Dimethyl-L-arginine" patented technology

The invention belongs to the technical field of immunotherapy. Firstly, dimethylarginine is found to effectively inhibit in-vitro proliferation of T and B cells, so a mechanism of ADMA and SDMA for inhibiting T and B cell proliferation in vivo is studied, and it is found that the ADMA and SDMA induced mitochondrial ROS generation is realized by activating AGXT2 enzyme, and the ADMA and SDMA are converted into a new substance DMGV through the AGXT2 enzyme, thereby the ADMA, the SDMA and the DMGV can effectively inhibit the proliferation of T and B cells; and the ADMA is converted into L-citrulline by dimethylamine hydrolase (DDAH), so the amount of ADMA that enters mitochondria, is converted into DMGV and functions is reduced, and a specific DDAH inhibitor PD404182 is the same as ADMA to suppress T cell proliferation. Therefore, the dimethylarginine, the derivatives thereof and the substances for specifically inhibiting degradation of the dimethylarginine are expected to provide a new direction for treating T and B cell mediated diseases by inhibiting abnormal proliferation of T and B cells.

The invention relates to a zymologic method for circularly testing the activity of dimethyl arginine dimethylamine hydrolytic enzyme, and a diagnostic reagent thereof. In a designed product detection method, hydrolysis of asymmetric dimethyl arginine is catalyzed by dimethyl arginine dimethylamine hydrolytic enzyme in a tissue sample to generate citrulline; in a novel design method, citrulline is made to continuously react with an enzyme circular reaction system consisting of citrulline hydrolytic enzyme (EC 3.5.1.20), ornithine carbamoyltransferase (EC 2.1.3.3) and a substrate of the ornithine carbamoyltransferase, so that the reaction sensitivity is greatly enhanced, and the yield of the citrulline is proportional to the activity of the dimethyl arginine dimethylamine hydrolytic enzyme in the sample; and the aim of testing the activity of the dimethyl arginine dimethylamine hydrolytic enzyme in the sample can be fulfilled by testing the generating rate of ammonia in the circular enzyme reaction system. A reagent can be a dry powder reagent, a liquid reagent, a single-dose reagent, a double-dose agent or a multi-dose agent.

The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (GFR), in an animal. GFR can be useful in the diagnosis and treatment of kidney disease or dysfunction. In various aspects, the disclosure is directed to the use of free symmetrical dimethylarginine (SDMA) and creatinine in blood samples from animals, in particular cats and dogs, to determine glomerular filtration rate and kidney disease.